{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:17:16Z","timestamp":1776467836540,"version":"3.51.2"},"reference-count":53,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,6,29]],"date-time":"2005-06-29T00:00:00Z","timestamp":1120003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:bold> Background:\u2002<\/jats:bold> Solid organ transplant recipients (OTRs) are a growing population at high risk for cutaneous neoplasms, resulting in significant post\u2010transplant morbidity and mortality. Management of malignant and pre\u2010malignant cutaneous lesions in transplant recipients is challenging, making prevention of such neoplasms paramount. The objectives of the present study are to review and analyze systemic strategies for chemoprevention of malignant and pre\u2010malignant cutaneous neoplasms in OTRs.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> MEDLINE and PubMed searches were performed to identify studies with original data quantifying the effects of systemic agents on the development of malignant cutaneous neoplasms in patients with solid organ transplants.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> We identified nine studies describing 111 transplant recipients that quantified the effects of oral retinoids on cutaneous neoplasms. A majority of the studies found a decrease in the number of malignant and pre\u2010malignant cutaneous lesions in patients treated with systemic retinoids, with several studies noting increased benefit in those patients with multiple previous skin cancers. Multiple studies described a rebound effect, with increased numbers of neoplasms occurring following discontinuation of retinoids. Side effects often limited dosing, but required discontinuation of retinoids in a minority of patients. No studies were identified that adequately quantified the effects of other systemic agents on skin cancer incidence in this population.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Although systemic retinoids are frequently used for chemoprevention of cutaneous malignancies in OTRs, the data supporting their use are composed largely of small uncontrolled case reports and case series. However, the available data suggest that retinoids have chemopreventative effects in this population. Although optimal dosing and indications for initiation of systemic retinoid therapy are not conclusive from the data, it suggests that retinoids are most effective in patients with multiple previous non\u2010melanoma skin cancers. Side effects and beneficial effects were noted across a wide range of doses, suggesting that retinoids should be initiated at a low dose and increased as tolerated to a minimally effective dose. Further investigation through randomized controlled trials is needed to further clarify the tolerability and efficacy of multiple dosing regimens on the incidence of pre\u2010malignant and malignant lesions in transplant recipients. The therapeutic role of other systemic agents in the transplant population has not been established.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2005.00412.x","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T11:43:18Z","timestamp":1282218198000},"page":"726-734","source":"Crossref","is-referenced-by-count":54,"title":["Systemic strategies for chemoprevention of skin cancers in transplant recipients"],"prefix":"10.1111","volume":"19","author":[{"given":"Bradley T","family":"Kovach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hunter H","family":"Sams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stasko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,24]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.30150.x"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.146.s61.2.x"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90239-2"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04976.x"},{"key":"e_1_2_9_6_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2340\/00015555-70491494","article-title":"Skin lesion in renal transplant patients after 10\u201323\u2003years of immunosuppressive therapy","volume":"70","author":"Blohme I","year":"1990","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"e_1_2_9_7_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2340\/0001555572115119","article-title":"Skin cancer after renal transplantation: the causal role of azathioprine","volume":"72","author":"Taylor AE","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.3.301"},{"key":"e_1_2_9_9_2","first-page":"2763","article-title":"Posttransplant malignancies in pediatric organ transplant recipients","volume":"26","author":"Penn I","year":"1994","journal-title":"Transplant Proc"},{"key":"e_1_2_9_10_2","first-page":"1383","article-title":"De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation","volume":"25","author":"Sheil AG","year":"1993","journal-title":"Transplant Proc"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2001.1119"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30250-8"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70525-6"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70185-4"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199603150-00008"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199003000-00006"},{"key":"e_1_2_9_17_2","first-page":"459","article-title":"Decreased skin cancer after cessation of therapy with transplant\u2010associated immunosuppressants","volume":"137","author":"Otley CC","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.00144.x"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1998.tb00712.x"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199503150-00013"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/22.12.1955"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/372107a0"},{"key":"e_1_2_9_23_2","first-page":"483","article-title":"Inhibition of tumor promoter\u2010induced transformation by retinoids that transrepress AP\u20101 without transactivating retinoic acid response element","volume":"56","author":"Li JJ","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/me.7.10.1347"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.33.3.690-695.1995"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20010101)91:1<8::AID-IJC1007>3.0.CO;2-H"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2001.6346"},{"key":"e_1_2_9_28_2","first-page":"92","article-title":"Retinoids in chemoprevention of cancer","volume":"17","author":"Verma AK","year":"2003","journal-title":"J Biol Regul Homeost Agents"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12504718"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.1.61"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)01837-1"},{"key":"e_1_2_9_32_2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.1985.3.6.751","article-title":"Inhibition of phorbol ester\u2010induced human epidermal ornithine decarboxylase activity by oral compounds: a possible role in human chemoprevention studies","volume":"3","author":"Loprinzi CL","year":"1985","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_33_2","first-page":"1281","article-title":"Chemoprevention of human actinic keratoses by topical 2\u2010(difluoromethyl)\u2010dl\u2010ornithine","volume":"9","author":"Alberts DS","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/22.1.83"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/19.5.723"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<667::AID-IJC10>3.0.CO;2-Y"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12495.x"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2002.00635.x"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.6.751"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890460061007"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04561.x"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01324.x"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70122-X"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y"},{"key":"e_1_2_9_45_2","first-page":"717","article-title":"Treatment of cutaneous neoplasia with etretinate in renal transplant recipients","volume":"68","author":"Shuttleworth D","year":"1988","journal-title":"Q J Med"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92292-A"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247478"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1933"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1998.tb00926.x"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02765.x"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2002.00613.x"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(02)00456-4"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)01831-0"},{"key":"e_1_2_9_54_2","first-page":"657","article-title":"Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants","volume":"10","author":"Carbone PP","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2005.00412.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2005.00412.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T01:22:13Z","timestamp":1696900933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2005.00412.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,24]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1399-0012.2005.00412.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2005.00412.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,24]]}}}